Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
View original at nasdaq.comTop Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Initial safety, tolerability, pharmacokinetic, and immune data for MDX2001 are expected in the first half of 2027.
60% confidenceKiniksa raised its full-year 2026 net product revenue guidance for Arcalyst to $980 million to $995 million.
60% confidenceProMIS expects to report topline 12-month results from the PRECISE-AD trial in the first quarter of 2027.
60% confidenceOPKO expects full-year 2026 total revenue of $560 million to $580 million.
60% confidencePrelude expects an IND application submission for PRT13722 by mid-2026 and a Phase 1 study initiation in ER-positive breast cancer in the second half of 2026.
60% confidenceEnrollment for the MDX2301 Phase 1 trial is expected to be completed in Q3 2026, with initial data anticipated in late 2026 or early 2027.
60% confidenceOPKO forecasts Q3 2026 revenue of $131 million to $142 million.
60% confidenceMapLight plans to engage the FDA at an End-of-Phase 2 meeting to discuss the path forward for ML-007C-MA in schizophrenia, including the design of a Phase 3 trial.
60% confidenceThe VISTA trial is designed to enroll approximately 300 participants, with topline results expected in the second half of 2027.
60% confidence
